medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2012, Number 2

<< Back Next >>

Rev Biomed 2012; 23 (2)

Bilophila wadsworthia Infections: Laboratory diagnoses of an antimicrobial resistant, slow growing, difficult, and important strict anaerobe

Quesada-Gómez C

Language: Spanish
References: 28
Page: 65-70
PDF size: 235.08 Kb.


ABSTRACT

Bilophila wadsworthia is an asaccharolytic, Gram-negative, bile-resistant, catalase-positive bacillus that is often urease positive and able to reduce nitrate to nitrite. Growth is stimulated by taurine, which is a cysteine derivative and major organic solute in humans. Bilophila have been recovered from specimens of patients with perforated appendicitis, otitis external, brain abscesses, soft tissue abscesses, from joint fluid, and from blood. In addition, Bilophila has been isolated from fecal material. This bacterium has been linked in various infections in humans, but it is an anaerobic bacteria with slow growth, making it difficult to cultivate and identify in the laboratory. It is also worth noting that Bilophila has significant resistance to antibiotics traditionally used in hospitals for the treatment of anaerobic infections. These reasons make it necessary to review and analyze the clinical significance of this anaerobic bacteria, to make the correct future diagnoses, and to acquire and report epidemiologic data from Latin-American hospitals on this and other anaerobic infections.


REFERENCES

  1. Baron EJ, Curren M, Henderson G. Bilophila wadsworthia isolates from clinical specimens. J Clin Microbiol 1992; 30: 1882-4.

  2. Baron EJ. Bilophila wadsworthia: a unique Gramnegative anaerobic rod. Anaerobe 1997; 3: 83-6.

  3. Laue H, Smits TH, Schumacher UK, Claros MC, Hartemink R, Cook AM. Identification of Bilophila wadsworthia by specific PCR wich targets the taurine: pyruvate aminotransferase gene. FEMS Microbiol Let 2006; 261: 74-9.

  4. Urbán E, Hortobágyi A, Szentpáli K, Nagy E. Two intriguing Bilophila wadsworthia cases from Hungary. J Med Microbiol 2004; 53: 1167-9.

  5. Baron EJ, Citron DM. Anaerobic Identification flowchart using minimal laboratory resources. Clin Infect Dis 1997; 25(2): S143-6.

  6. Finegold S, George WL. Anaerobic Infections in Humans. Academic Press, San Diego, CA, EEUU. 1989.

  7. Jousimies-Somer H, Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic gram-negative bacteria (excluding Spirochetes). Clin Infect Dis 2002; 35(1): S17-21.

  8. Schumacher UK, Bless D, Plinkert PK, Laue H, Werner H. Bilophila wadsworthia in ear infections: a report of tree cases. Anaerobe 1999; 5: 371-2.

  9. Mosca A, D’Alagni M, Del Prete R, De Michele GP, Summanen P, Finegold S., Miragliotta G. Preliminary evidence of endotoxic activity of Bilophila wadsworthia. Anaerobe 1995; 1: 21-4.

  10. Avidan O, Kaltageser E, Pechatnikov I, Wexler H, Shainskaya A, Nitzan Y. Isolation and characterization of porins from Desulfovibrio piger and Bilophila wadsworthia: structure and gene sequencing. Arch Microbiol 2008; 190: 641-50.

  11. McOrist S, Keller L, McOrist AL. Search for Lawsonia intracellularis and Bilophila wadsworthia in malabsorption-deseased chickens. Canadian J Veterin Res 2003; 67: 232-4.

  12. Kasten MJ, Rosenblatt J, Gustafson DR. Bilophila wadsworthia bacteremia in two patients with hepatic abscesses. J Clin Microbiol 1992; 30: 2502-3.

  13. Warren YA, Citron D, Merriam C, Goldstein EJC. Biochemical Differentiation and Comparison of Desulfovibrio Species and Other Phenotypically Similar Genera. J Clinic Microbiol 2005; 43: 4041-5.

  14. Jousimies-Somer HR, Summanen P, Citron DM, Baron E J, Wexler HM, Finegold SM. Wadsworth Anaerobic Bacteriology Manual. 6th Ed. Belmont, CA: Star Publishing. 2002.

  15. Goldstein E, Citron DM, Warren Y, Tyrrell K, Vreni Merriam C, Fernandezi H. In vitro activity of Moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-55.

  16. Hunt S, Marina M, Citron DM. Bilophila wadsworthia clinical isolates compared by polymerase chain reaction fingerprinting. Clinic Infect Dis 1997, 25(2): S291-4.

  17. Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005; 49: 4413-7.

  18. Molitoris D, Vaisanen ML, Bolaños M, Finegold SM. In vitro activities of DX-619 and Four comparator agents against anaerobic bacterial isolates. Antimicrob Agents Chemother 2006; 50: 1887-9.

  19. Summanen P, Wexler HM, Lee K, Becker S, Garcia MM, Finegold SM. Morphological response of Bilophila wadsworthia to Imipenem: Correlation with properties of Penicillin-Binding Proteins. Antimicrob Agents Chemother 1993; 37: 2638-44.

  20. Summanen P. Comparison of effects of medium composition and atmospheric conditions on detection of Bilophila wadsworthia β-lactamase by Cefinase and Cefinase plus methods. J Clinic Microbiol 2000; 38: 733-6.

  21. Wexler H, Molitoris D, St. John S, Vu A, Read E, Finegold S. In vitro activities of Faropenem against 579 strains of anaerobic bacteria. Antimicrob Agents Chemother 2002; 46: 3669-75.

  22. Tanaka K, Mikamo H, Nakao K, Watanabe K. In vitro antianaerobic activity of DX-619, a new desfluoro(6) quinolone. Antimicrob Agents Chemother 2006; 50: 3908-13.

  23. Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K. Comparative in vitro activities of Ertapenem (MK-0826) against 1001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2000; 44: 2389-94.

  24. Molitoris E, Wexler HM, Finegold SM. Sources and antimicrobial susceptibilities of Campylobacter gracilis and Sutterella wadsworthensis. Clinic Infect Dis 1997; 25(2): S264-5.

  25. Goldstein EJC. Intra-abdominal Anaerobic Infections: Bacteriology and Therapeutic Potencial of newer antimicrobial Carbapenem, Fluoroquinolone, and Desfluoroquinolone therapeutic agents. Clinic Infect Dis 2002; 35(1): S106-11.

  26. Barboza E, Solomkin J, Goldstein EJ, Castillo M, Alvarado R, Barboza A, Teppler H. Nuevo agente betalactámico en el manejo de la sepsis intra-abdominal: estudio de fase III, doble ciego y randomizado del Ertapenem vs. Piperacilina/Tazobactam. Revista de Gastroenterología del Perú 2003; 23:192-8.

  27. Wexler H, Molitoris E, Molitoris D, Finegold S. In vitro activity of Telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. J Antimicrob Chemother 2001; 47:467-9.

  28. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: Worrisome developments. Clinic Infect Dis 2004; 39:92-7.




2020     |     www.medigraphic.com